Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Oct;20(2):10-15.
doi: 10.17925/EE.2024.20.2.3. Epub 2024 Apr 8.

New Trends in Treating Cushing's Disease

Odysseas Violetis  1 , Krystallenia I Alexandraki  1
Affiliations
Editorial

New Trends in Treating Cushing's Disease

Odysseas Violetis et al. touchREV Endocrinol. 2024 Oct.

Abstract

Rates of recurrence and/or persistence of Cushing's disease after surgical treatment are high. Recently, advances in molecular insights and a better understanding of pathophysiology have enabled the development of potential therapeutic targets that could control adrenocorticotropic hormone (ACTH) and cortisol secretion or even reduce tumour cell proliferation. At the pituitary level, pasireotide is an approved somatostatin receptor ligand, and compounds targeting cell cycle regulation, cell signalling and epigenetics are now under investigation. Levoketoconazole and osilodrostat are novel steroid inhibitors, and relacorilant overcomes the adverse effects of mifepristone. Adrenal ACTH receptor blockage and immunotherapy could also play a role.

Keywords: Cushing’s disease; immunotherapy; levoketoconazole; novel drugs; osilodrostat; pasireotide; relacorilant.

PubMed Disclaimer

Conflict of interest statement

Disclosures: Odysseas Violetis and Krystallenia I Alexandraki have no financial or non-financial relationships or activities to declare in relation to this article.

Figures

Figure 1:
Figure 1:. The main mechanism of action of the novel drugs for Cushing’s disease
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Nieman LK, Biller BMK, Findling JW. et al. Treatment of Cushing's syndrome: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:2807–31. doi: 10.1210/jc.2015-1818. - DOI - PMC - PubMed
    1. Alexandraki KI, Grossman AB. Therapeutic strategies for the treatment of severe Cushing's syndrome. Drugs. 2016;76:447–58. doi: 10.1007/s40265-016-0539-6. - DOI - PubMed
    1. Alexandraki KI, Kaltsas GA, Isidori AM. et al. Long-term remission and recurrence rates in Cushing’s disease: Predictive factors in a single-centre study. Eur J Endocrinol. 2013;168:639–48. doi: 10.1530/EJE-12-0921. - DOI - PubMed
    1. Roelfsema F, Biermasz NR, Pereira AM. Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: A structured review and meta-analysis. Pituitary. 2012;15:71–83. doi: 10.1007/s11102-011-0347-7. - DOI - PMC - PubMed
    1. Broersen LHA, Jha M, Biermasz NR. et al. Effectiveness of medical treatment for Cushing’s syndrome: A systematic review and meta-analysis. Pituitary. 2018;21:631–41. doi: 10.1007/s11102-018-0897-z. - DOI - PMC - PubMed

Publication types

LinkOut - more resources